Ictastan

Emtricitabine and Tenofovir Disoproxil Succinate, the active ingredients in Ictastan, are nucleoside/nucleotide reverse transcriptase inhibitors presented as oral tablets for oral use. They are indicated for the treatment of HIV‑1 infection in combination with other antiretroviral agents.

GNH USA supplies Ictastan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ictastan is a nucleoside/nucleotide reverse transcriptase inhibitor used in the management of HIV‑1 infection. It is incorporated into combination regimens to achieve viral suppression.

- HIV‑1 infection (adults): reduces viral load when used with other antiretrovirals. - Chronic HIV‑1 infection (treatment‑naïve patients): forms part of first‑line regimen. - HIV‑1 infection (pediatric patients): used under specialist supervision as part of combination therapy.

Common side effects are generally mild to moderate and may resolve with continued therapy.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Fatigue: reduced energy levels. - Diarrhea: loose stools. - Insomnia: difficulty sleeping. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Lactic acidosis: metabolic disturbance requiring immediate medical attention. - Severe hepatotoxicity: liver enzyme elevation or failure. - Renal toxicity: impaired kidney function. - Hypersensitivity reactions: including fever and swelling. - Bone mineral density loss: increased risk of fractures. - Severe skin reactions: such as Stevens‑Johnson syndrome.

Patients should be monitored for organ function and adherence to therapy. - Renal function monitoring: assess creatinine clearance before and during treatment. - Hepatic function monitoring: check liver enzymes regularly. - Pregnancy considerations: evaluate risk‑benefit ratio under specialist guidance. - Drug resistance risk: ensure adherence to prevent viral resistance. - Adherence importance: maintain consistent dosing schedule. - Store below 25°C: keep in the original pack, protect from moisture.

Ictastan may interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis. - Rifampin: reduces plasma concentrations of tenofovir. - Concomitant nephrotoxic agents: may exacerbate renal toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may affect renal function. - Antacids containing aluminum or magnesium: can reduce absorption of emtricitabine. - Other NRTIs: monitor for additive toxicity.